|
|
|
| Discussions for Tongjitang Chinese Medicines Co. |
 |
|
 |
EXPLODING STOCK PICK SOLVING THE FUTURE ENERGY CRISIS WWPW @ http://www.stockexploder.com
Dear Friends: Here is our New Exploding Stock Pick -WWPW IS GOING TO DOMINATE THE FUTURE WIND WORKS POWER (WWPW) THE FUTURE OF ENERGY [link] WWPW LIST OF GREAT PROJECTS [link] U.S. DEPARTMENT OF ENERGY Wind Energy Could Produce 20 Percent of U.S.... Ballard Ballard - |
|
Positive data from the Phase 2 trial of ISIS’s diabetes drug
Isis Pharmaceuticals Inc (ISIS) recently reported that its experimental diabetes drug, ISIS 113715, showed consistent and statistically significant reduction in glucose levels in a mid-stage trial. To read more details about the drug and its market potential, read a FREE report on ISIS 113715 at: [link]... babu - |
|
FDA delayed the approval of Fampridine SR
The FDA has delayed the approval decision of Acorda Therapeutics Inc.’s (ACOR) Fampridine SR for the treatment of walking disability associated with multiple sclerosis (MS) till January 22, 2010. To read about the event, go to report available for FREE at [link] pinky das - |
|
Upcoming FDA decision of a small-cap company’s drug for walking disability associated with multiple sclerosis on October 22
The FDA will make a decision on the approval of a small-cap company’s drug for walking disability associated with multiple sclerosis on October 22. If approved, this could become a breakthrough treatment for walking disability associated with multiple sclerosis. To find out what the chances are of this new drug being approved, how the drug... ritushreeya - |
|
美股价值投资讨论群
我创建了一个专门用于讨论美股基本面的QQ群:89851125 。希望广大热衷于价值投资的朋友加入进来，共同探讨，共同提高。 如果你以技术分析为自 己的投资依据，请寻找其它适合你的群组，如果你是听消息，凭感觉 ，看不懂财务报表的人，请过几年再来。相信每个人基于自己所在行 业及对周围... calvin - |
|
FDA decision regarding approval of an Opthalmic (eye) drug is coming soon.
The FDA will be review a new drug in the opthalmic (eye) area on September 12th. If this drug gets the FDA approval, the stock could see a substantial increase in valuation because the estimated Peak Sales of the drug compared to its current market capitalization is at approximately 70%. To read about which company, what drug, which... tanu - |
|
A FREE report on the approval of a new Gout Drug
An upcoming treatment by a small cap company for Gout to face FDA decision on approval shortly. Gout has traditionally been a difficult disease to treat. To read about whether this small cap company has chances to get their drug approved, get a FREE report at our website: NEWBIOMEDICINE.COM babu - |
|
Free report on upcoming FDA panel decision of Corvue on Tuesday
FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by the FDA will increase significantly. If the drug gets approved by the FDA, it is estimated to achieve Peak sales of $350 million. To read about our expectation on the Panel decision, the... sudip - |
|
Upcoming FDA panel decision on Corvue next week
FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by the FDA will increase significantly. If the drug gets approved by the FDA, it is estimated to achieve Peak sales of $350 million. To read about our expectation on the Panel decision, the... sudip - |
|
upcoming event analysis on FDA panel for Corvue
FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by the FDA will increase significantly. If the drug gets approved by the FDA, it is estimated to achieve Peak sales of $350 million. To read about our expectation on the Panel decision, the... babu - |
| Discussions 1 - 10 of 53 Older » | |
| XML |
|
| Google Home - Terms of Service - Privacy Policy |
©2009 Google
discussions